カレントテラピー　33-10　サンプル page 17/32

このページは カレントテラピー　33-10　サンプル の電子ブックに掲載されている17ページの概要です。
秒後に電子ブックの対象ページへ移動します。
「電子ブックを開く」をクリックすると今すぐ対象ページへ移動します。

概要：
カレントテラピー　33-10　サンプル

Current Therapy 2015 Vol.33 No.10 39変貌するパーキンソン病治療983参考文献1）Perry EK, Kilford L, Lees AJ, et al：Increased Alzheimerpathology in Parkinson’s disease related to antimuscarinicdrugs. Ann Neurol 54：235-238, 20032）Hoehn MM, Yahr MD：Parkinsonism：onset, progressionand mortality. Neurology 17：427-442, 19673）Hoehn MM：The natural history of Parkinson’s disease inthe pre-levodopa and post-levodopa eras. Neurol Clin 10：331-339, 19924）Constantinescu R, Romer M, McDermott MP, et al；CALMPDInvestigators of the Parkinson Study Group：Impact ofpramipexole on the onset of levodopa-related dyskinesias.Mov Disord 22：1317-1319, 20075）Rascol O, Brooks DJ, Korczyn AD, et al；056 Study Group：Development of dyskinesias in a 5-year trial of ropiniroleand L-dopa. Mov Disord 21：1844-1850, 20066）Gray R, Ives N, Rick C, et al；PD Med Collaborative Group：Long -term effectiveness of dopamine agonists and monoamineoxidase B inhibitors compared with levodopa as initialtreatment for Parkinson’s disease（PD MED）：a large,open-label, pragmatic randomised trial. Lancet 384：1196-1205, 20147）LeWitt PA：Clinical trials of neuroprotection in Parkinson’sdisease：long -term selegiline and alpha-tocopherol treatment.J Neural Transm Suppl 43：171-181, 19948）Stocchi F, Rascol O, Kieburtz K, et al：Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinsondisease：the STRIDE-PD study. Ann Neurol 68：18-27, 20109）Verhagen Metman L, Del Dotto P, van den Munckhof P, etal：Amantadine as treatment for dyskinesias and motor fluctuationsin Parkinson’s disease. Neurology 50：1323-1326,199810）Ory-Magne F, Corvol JC, Azulay JP, et al；NS-Park CICNetwork：Withdrawing amantadine in dyskinetic patientswith Parkinson disease：the AMANDYSK trial. Neurology82：300-307, 201411）Murata M, Horiuchi E, Kanazawa I：Zonisamide has beneficialeffects on Parkinson’s disease patients. Neurosci Res41：397-399, 200112）Suchowersky O, Gronseth G, Perlmutter J, et al；QualityStandards Subcommittee of the American Academy of Neurology：Practice Parameter：neuroprotective strategies andalternative therapies for Parkinson disease（an evidencebasedreview）：report of the Quality Standards Subcommitteeof the American Academy of Neurology. Neurology 66：976-982, 200613）Fahn S, Oakes D, Shoulson I, et al；Parkinson Study Group：Levodopa and the progression of Parkinson’s disease. N EnglJ Med 351：2498-2508, 200414）Schapira AH：The use of rasagiline in Parkinson’s disease. JNeural Transm Suppl 71：157-161, 200615）Hauser RA, Ellenbogen AL, Metman LV, et al：Crossovercomparison of IPX066 and a standard levodopa formulationin advanced Parkinson’s disease. Mov Disord 26：2246-2252,201116）Olanow CW, Kieburtz K, Odin P, et al；LCIG Horizon StudyGroup：Continuous intrajejunal infusion of levodopa-carbidopaintestinal gel for patients with advanced Parkinson’s disease：a randomised, controlled, double-blind, double-dummystudy. Lancet Neurol 13：141-149, 201417）LeWitt PA, Huff FJ, Hauser RA, et al：Double-blind study ofthe actively transported levodopa prodrug XP21279 in Parkinson’sdisease. Mov Disord 29：75-82, 2014